Alphamab Oncology (9966.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG0330A1013
Alphamab Oncology financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 640.08 m CNY | 567.08 m CNY |
| Gross profit | 533.80 m CNY | 438.32 m CNY |
| EBIT | 93.12 m CNY | -153.46 m CNY |
| Net income | 166.34 m CNY | -113.77 m CNY |
| Diluted EPS – continuing operations | 0.15 CNY | -0.12 CNY |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Alphamab Oncology
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
More stocks
- Lem Holding SA (LEHN.SW)
- Cannae Holdings, Inc. (CNNE)
- Apex Dynamics Inc. (4583.TW)
- Archicom SA (ARH.WA)
- PROSPECT CAPITAL CORP (PSEC)
- Shenzhen Bingchuan Network Co Ltd (300533.SZ)
- Acomo NV (ACOMO.AS)
- Tigerair Taiwan Co. Ltd. (6757.TW)
- Doctorglasses Chain Co Ltd (300622.SZ)
- Alandsbanken Abp (ALBAV.HE)
- Sto SE & Co KgaA (STO3.DE)
- HJ ShipBuilding & Construction Co Ltd (097230.KS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.